Invivyd finds FDA more open to alternative to Covid vaccines

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Happy Labor Day, people! Summer’s over. Have you booked for JPM26 travel yet? 

A market opportunity on Covid

Invivyd, a small biotech company based in Massachusetts, is developing an experimental monoclonal antibody designed to protect against Covid-19 infection like a vaccine does, but without the real or perceived limitations of vaccines, particularly the politically damaged mRNA shots from Pfizer and Moderna.